Description
2 mg (2000 mcg) CJC-1295 (no DAC)
DAC conjugated CJC 1295 (Receptor Grade) is an hGH secretogue that is unique by way of an additional lysine molecule that is added to facilitate the DAC complex. This conjugation makes for a much longer half-life. DAC CJC 1295 tends to have a very limited availability everywhere due to expense and difficulty to manufacture. CJC 1295 DAC is a exceptionally designed peptide and is known for being the finest of the hGH secretogues. Receptor grade: 98%+ pure 2000mcg / 2ml glass vial. THIS PRODUCT IS INTENDED FOR RESEARCH PURPOSES ONLY. CAN BE HARMFUL IF USED INAPPROPRIATELY.
In the healthy human body, large amounts of growth hormone are stored in the pituitary. The cells within the pituitary release growth hormone in response to signalling by GHRH (Growth Hormone Releasing Hormone), Ghrelin (of which GHRPs – Growth Hormone Releasing Peptides – are mimetics), and are inhibited from releasing these stores by Somatostatin. GHRH and Ghrelin act on different populations of somatotropes (GH releasing cells). GHRP/Ghrelin increases the number of somatotropes releasing GH but not the amount released by each cell;
GHRH affects both the number of secreting cells and – moreso – the amount they each secrete. [1] GHRH and Ghrelin are released in specific patterns that vary depending on event and environment: post-exercise, in response to slow wave sleep, in certain stages of life and physical development, and so on.
Most people (even the diseased) continue to possess the ability to make GH in the pituitary. The problem is in the signalling of the pituitary to release it (and make more). So yes CJC is meant to replace the external administration of GH in some (but not all) cases.Even most people with diseases that affect growth hormone secretion retain the ability to continue to make GH in their pituitaries. The disease states and symptoms result, most typically, in altered (dysfunctional) GH release signalling and this also affects the ability of the pituitary to continue to make more GH.
CJC-1295 Administration
In “Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults“, Sam L. Teichman, et al. Journal of Clinical Endocrinology & Metabolism 91(3):799-805, sixty-six healthy normal men and women aged 21-61 were administered various doses of CJC-1295 (long-lasting GHRH analog). The CJC-1295 was administered in a single dose and again in some groups 7 days later and other groups 14 days later. For the reason that we are only examining a week’s worth of data only the initial dose is of interest. Blood samples were collected before dosing and then at 15, 30, and 60 minutes and 2, 3, 4, 6, 8, 10, 12, and 24 hours afterdosing; and then every 8 hours on days 2–3, then daily on days 4, 5, 6, 7.
The doses administered were: 30mcg/kg; 60mcg/kg; 125mcg/kg; 250mcg/kg
CJC-1295 (Tyr-DAla-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys- Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu- Gln-Asp-Ile-Leu-Ser-Arg-Lys-(Maleimidopropionyl)- NH2) = Half-life measured in days, – Ref-6
When CJC-1295 was administered at 30mcg/kg; 60mcg/kg; 125mcg/kg and 250mcg/kg the total GH levels (area under the curve (AUC)) were respectively:
AUC: 758, 969, 977, and 1370 ng/ml per hour
Keep in mind that for a 80kg adult the 30mcg/kg dosing amounts to 2.4mgs of CJC-1295 per week and the 60mcg/kg dosing amounts to 4.8mgs of CJC-1295.
So 2.4 mgs of CJC-1295 produced an AUC of 758 ng/ml per hour.
When synthetic Growth Hormone (Humatrope) was administered at the equivalent of 22iu (in someone weighing 80+ kg) the following GH levels (area under the curve (AUC)) were reached:
AUC Intramuscular: 495 +/- 106
AUC Subcutaneous: 585 +/- 90
NOTES:
Lys = linker to the Drug Affinity Complex (aka (Maleimidopropionyl))
“Since GH is released in a pulsatile manner and a higher level of GH is observed between 15 and 30 min after subcutaneous administration of GH-RH analogues, hydrolysis by trypsin-like enzymes could not affect the result of stimulation.” – Potent Trypsin-resistant hGH-RH Analogues, JAN IZDEBSKI, J. Peptide Sci. 10: 524–529 (2004)
The analog in the above quoted study resisted degradation for 30 minutes. The quote implies that if your analog can last 30 minutes it has tapped out the potential for a single pulse.
Since another pulse won’t be generated for about 2.5 – 3 hours analogs that last more than 30 minutes up to 3 hours are not any more beneficial.
You would need an analog that kept growth hormone releasing hormone around beyond 3 hours to have it trigger a second pulse.
Otherwise dosing the 30 minute analog every 3 hours will maximize GH output OR you could just use an analog such as CJC-1295 which lasts for many days and will trigger several GH pulses a day for several days on a single dose.
CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a growth hormone releasing hormone (GHRH) analog.
CJC1295 was invented by ConjuChem, a Canadian biotechnology company. ConjuChem initiated clinical trials for CJC-1295 during the mid-2000s. The objective of the drug was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous HGH are presumed to increase lipolysis (fat loss). The trial was ultimately successful for most research subjects, but the drug’s marketing stalled when three of the trial’s patients suffered a myocardial infarction
Uses and Benefits of CJC-1295
- Basically CJC-1295 is a long acting growth hormone releasing hormone (GHRH) analog.
- Single dose of 60 ug/kg of CJC-1295 results in elevated levels of growth hormone while maintaining the GH secretion. However a dose of 30 ug/kg of CJC-1295 given weekly is ideal in maintaining the level of growth hormone.
- It has the ability to bioconjugate with serum albumin to increase its half life and therapeutic window.
- CJC-1295 helps in promoting slow wave sleep. It is also known as deep sleep which is the part of sleep responsible for maximum muscle growth and memory retention level.
- Also it is beneficial in treating visceral fat deposits in obese AIDS patients and increasing levels of exogenous HGH to increase fat loss.
About the Formation, Uses and Benefits of CJC-1295 DAC Peptide
Over a period of time, science has shown an amazing growth in the field of medicine to let people live a better life with better health. Among those inventions is the invention of peptides which is targeted towards providing a solution to several health issues with human beings. There are various types of peptides available in the market having their specific use in the life of a person. Here in this article, we are going to talk about the CJC-1295 DAC peptide in particular, regarding its formation, molecular make up, uses and benefits, ideal dose and various other major aspects that one should know before using this peptide for effective results.
Basically CJC-1295 is a long acting growth hormone releasing hormone (GHRH) analog. GHRH, also known as growth hormone releasing factor or somatocrinin, is 44-amino acid peptide hormone which is produced by the arcuate nucleus in the hypothalamus. It stimulates secretion of growth hormone from the pituitary gland and is released in a pulsatile manner to ultimately stimulate pulsatile release of growth hormone. This pulsatile release in various peptides is the root cause for half life of the peptide due to an enzyme called dipeptidylaminopeptidase IV (DPP-IV). Thus the need for increasing the life and bioavailability of peptide compelled pharmaceutical companies to come up with technologies like PEGylation to make peptides even more effective.
Thus CJC-1295 which is a synthetic modification of GHRH with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively, is applied with Drug Affinity Complex (DAC) technology to its GHRH to increase its half-life. CJC-1295 DAC peptide carefully and covalently combines to circulate albumin after subcutaneous (SC) administration leading to lengthen its half life from seven minutes to more than seven days. With the help of highly effective bioconjugation process, hardly I % of CJC-1295 remain unreacted in vivo and CJC-1295 molecule attach itself to albumin easily for prolong half-life. There are several benefits that can be assured with CJC-1295 DAC after conducting its effective test on mice in clinical lab.
Its main function is to increase protein synthesis and stimulate new muscle tissue growth. It effectively curbs growth hormone (GH) deficiency in children to let them grow normally. CJC-1295 DAC leads to an increase in muscle mass and also adds to physical strength. It is also helpful in controlling skin aging and effective in reducing wrinkles. CJC-1295 DAC leads to re-growth of internal organs atrophied with age and result in hyperplasia to increase the number of muscle cells. Besides there are other benefits like increased bone density, strong immunity, faster recovery from injuries and lipolysis promotion to reduce body fat. As per dose recommendation, it is tested that a dose of 30 or 60 µg/kg is ideal to increase GH and insulin like growth factor (IGF-1) in healthy adults. Also due to long half-life and stability, taking CJC-1295 DAC 1-2 times per week would do the required job.
- Falutz, J et al. “A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.” AIDS. 2005 August 12;19(12):1279-87.
- Teichman, SL et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006 March 91(3):799-805. Epub 2005 December 13.
DISCLAIMER: the use of this substance is banned under the WADA anti-doping code in competitive sports!
